workplace
Drug testing in the workplace
A practical reference for HR and compliance teams on why employers test, what the federal framework requires, and how to choose a defensible panel and matrix.
·9 min read
Quick answer
Workplace drug testing is a structured screening program — most commonly urine-based — that employers use to deter substance use, manage safety risk, and comply with federal or industry requirements. Federally regulated employers must follow the SAMHSA Mandatory Guidelines and, for transportation, 49 CFR Part 40. Non-federal employers have broad latitude but face a patchwork of state laws, ADA obligations for prescription medication, and cannabis-employment-protection statutes that should be reviewed with counsel before launching a program.
Why employers test — the five common scenarios
Most workplace drug-testing programs fall into one of five operational categories. Each has a different evidentiary purpose, a different defensible cutoff and matrix, and a different set of legal exposures. Treating them as a single "drug test" line item is the most common reason programs run into trouble during a challenge.
Pre-employment testing is the most widespread category. It happens after a conditional offer of employment and screens for current or recent use before a candidate joins the workforce. Random testing is used in safety-sensitive industries — DOT-regulated employers are required to maintain a random program at minimum annual rates set by each modal administration. Post-accident testing follows a workplace incident that meets defined triggering criteria; for DOT-regulated employees, those triggers are codified in 49 CFR Part 40.
Reasonable-suspicion testing is ordered when a trained supervisor documents specific, contemporaneous, articulable observations of behavior consistent with impairment. Return-to-duty and follow-up testing apply to employees re-entering safety-sensitive functions after a prior violation, generally after evaluation by a Substance Abuse Professional under DOT rules. Each category should be addressed individually in a written policy.
The federal regulatory framework
Two federal regimes govern most regulated workplace testing in the United States. The Substance Abuse and Mental Health Services Administration (SAMHSA) publishes the Mandatory Guidelines for Federal Workplace Drug Testing Programs, which set the cutoffs, procedures, and laboratory-certification standards for federal civilian employees and contractors covered by the Drug-Free Workplace Act. The U.S. Department of Transportation incorporates SAMHSA's technical standards into 49 CFR Part 40, the procedural rule that applies to safety-sensitive transportation employees across the FMCSA, FAA, FRA, FTA, PHMSA, and USCG.
SAMHSA's urine guidelines specify a 5-substance panel — marijuana (THC), cocaine, amphetamines (including methamphetamine and MDMA), opiates (morphine, codeine, 6-AM), and PCP — with specific screening and confirmation cutoffs that programs are required to use without modification. SAMHSA has also authorized oral fluid as a federal matrix and has published separate oral-fluid guidelines. Hair testing is not yet a SAMHSA-authorized matrix for federal programs as of this writing.
Non-federal employers are not bound by SAMHSA cutoffs but commonly adopt them by reference to keep their programs defensible and consistent with industry practice. Programs that deviate from SAMHSA standards should document why and should expect to defend the deviation in any wrongful-discharge or unemployment-benefits proceeding that follows an adverse action.
Choosing a specimen matrix
Urine remains the dominant workplace matrix because of cost, the breadth of validated assays, and the depth of regulatory precedent. It reflects metabolite excretion over the prior hours to weeks and is well-suited to deterrence-oriented programs and post-employment monitoring. Urine is the only matrix authorized for most legacy federal programs and remains the default for DOT-regulated testing.
Oral fluid (saliva) testing has grown rapidly in workplace adoption since SAMHSA authorized it as a federal matrix. Oral fluid correlates better with recent use and impairment because it detects parent drug rather than long-tailed metabolites, which matters when the employer's concern is current fitness for duty rather than weekend behavior. Collection is observed and non-invasive, which reduces disputes and shy-bladder issues.
Hair testing extends the lookback window to roughly 90 days for a standard 1.5-inch sample. Some safety-sensitive employers value the long window for pre-employment screening, but hair is not SAMHSA-authorized for federal programs and faces ongoing scrutiny over potential bias in the published literature on melanin binding. Programs considering hair testing should document the business justification and consult counsel about disparate-impact exposure.
| Matrix | Typical window | Best for | Federal status |
|---|---|---|---|
| Urine | Hours to weeks (substance-dependent) | Deterrence, post-employment monitoring, DOT | SAMHSA-authorized; 49 CFR Part 40 |
| Oral fluid | Hours to ~72 hours | Recent-use, reasonable-suspicion, post-accident | SAMHSA-authorized (oral-fluid guidelines) |
| Hair | Up to ~90 days | Pre-employment lookback, forensic | Not SAMHSA-authorized |
| Blood | Hours to days | Post-accident, DUI, post-mortem | Limited workplace use |
Choosing a panel — SAMHSA-5, 10-panel, or expanded
Panel selection is a substantive policy decision, not a procurement detail. The SAMHSA-5 panel (THC, cocaine, amphetamines, opiates, PCP) is the federal minimum and remains common in pre-employment screening because it covers the substances of historical regulatory interest at standardized cutoffs. It is sufficient for many entry-level workplace programs and is the lowest-cost option.
Expanded 10-panel devices add benzodiazepines, barbiturates, methadone, propoxyphene or oxycodone, and MDMA — a configuration that has been industry-standard for non-federal workplace testing for decades. Modern 12-, 14-, 16-, and 17-panel devices add fentanyl, buprenorphine, oxycodone, K2/Spice, tramadol, EtG (alcohol metabolite), and additional opioid analytes. The trend in safety-sensitive private-sector and clinical programs has been steadily toward broader panels to address the synthetic-opioid epidemic and prescription-opioid misuse.
Fentanyl deserves specific attention. Standard opiate immunoassays do not detect fentanyl — programs operating in environments with significant illicit-fentanyl exposure (per CDC overdose data, now the largest share of synthetic-opioid mortality) must add a fentanyl-specific analyte if they want fentanyl coverage. As of this writing, fentanyl is not part of the SAMHSA mandatory panel.
Policy essentials — written policy, MRO review, confirmation testing
Every workplace testing program should be governed by a written policy distributed to employees before testing begins. The policy should identify which categories of testing the employer will perform, which positions are subject to which categories, the substances tested, the consequences of a confirmed positive or a refusal to test, the procedures for handling prescription-medication disclosures, and the rights employees have during the process. SAMHSA and the U.S. DOT publish model policy elements that programs can adapt.
A confirmed positive should never be the result of a single point-of-care screen. The industry standard — and the federal requirement for SAMHSA-regulated and DOT-regulated testing — is a two-step process: an initial immunoassay screen, followed by confirmation of any presumptive positive at a SAMHSA-certified laboratory using gas chromatography/mass spectrometry (GC/MS) or liquid chromatography/tandem mass spectrometry (LC-MS/MS). Confirmation distinguishes the targeted analyte from cross-reacting compounds and quantifies it precisely.
Confirmed laboratory positives are then reviewed by a Medical Review Officer (MRO) — a licensed physician with substance-abuse-testing training. The MRO contacts the donor, reviews any legitimate medical explanation (prescription medication, documented medical condition), and only reports a verified positive to the employer when no legitimate explanation accounts for the result. The MRO process is a procedural safeguard that protects both employees and employers from incorrect adverse actions.
Documentation that should accompany every program
A written policy with explicit testing categories and consequences. Chain-of-custody forms for every specimen. Supervisor training records for reasonable-suspicion observations. Records of random-pool selection procedures. MRO contact and reporting workflow. Records of any state-required notices, postings, or employee acknowledgments. Documentation of any reasonable-accommodation discussions under the ADA related to prescribed medication.
Special situations — ADA, prescription medication, and cannabis
The Americans with Disabilities Act (ADA), enforced by the Equal Employment Opportunity Commission (EEOC), restricts when employers can ask about prescription medication and how they can act on positive results explained by lawful prescriptions. Current illegal drug use is generally not protected, but a person in recovery, a person erroneously regarded as a current user, or a person whose positive result reflects a prescribed controlled substance for a disability may have ADA protection. Programs should route all medication-related discussions through the MRO rather than HR or the hiring manager.
State cannabis-employment-protection laws are the fastest-moving area in workplace testing. A growing number of states — including New York, New Jersey, California, Connecticut, Washington, Nevada, and others — restrict pre-employment testing for THC, prohibit adverse action based solely on a positive THC result, or extend protections to registered medical-marijuana patients. Federal employers, federal contractors, and DOT-regulated employees are not covered by these state protections and must continue to test for marijuana under federal rules.
Safety-sensitive carve-outs in state cannabis statutes vary considerably. Some states preserve the employer's right to test and act on a positive in any safety-sensitive role; others define safety-sensitive narrowly. Employers operating across multiple states should map their testing program to each jurisdiction rather than applying a single national policy by default.
Key takeaways
- ✓Workplace testing falls into five categories — pre-employment, random, post-accident, reasonable-suspicion, and return-to-duty — each with distinct procedural standards.
- ✓Federally regulated programs must follow SAMHSA Mandatory Guidelines and, for transportation, 49 CFR Part 40; non-federal programs commonly adopt those standards by reference.
- ✓Urine remains the dominant matrix; oral fluid is SAMHSA-authorized and growing in adoption because it correlates better with recent use and impairment.
- ✓The SAMHSA-5 panel is a regulatory minimum, not a comprehensive screen — fentanyl is not included and must be added separately when fentanyl coverage matters.
- ✓Every confirmed positive should pass through a two-step process: immunoassay screen, then GC/MS or LC-MS/MS confirmation at a SAMHSA-certified laboratory.
- ✓Medical Review Officer (MRO) review is the procedural safeguard that protects both employees and employers from incorrect adverse actions tied to prescription medications.
- ✓The ADA restricts how employers can act on prescription-medication-related positives; all medication discussions should route through the MRO.
- ✓State cannabis-employment-protection laws now restrict THC testing in a growing number of jurisdictions — multi-state employers should map their policy state-by-state with counsel.
Sources
- SAMHSA·Mandatory Guidelines for Federal Workplace Drug Testing Programs
- U.S. DOT·49 CFR Part 40 — Procedures for Transportation Workplace Drug and Alcohol Testing Programs
- SAMHSA·SAMHSA Workplace Resources — Drug-Free Workplace Programs
- U.S. DOT·DOT ODAPC — Frequently Asked Questions on 49 CFR Part 40
Information in this article is provided for educational reference and is not medical, legal, or clinical advice. Consult qualified professionals for guidance specific to your program.